Kissei Pharmaceutical boosts full-year financial forecast on strong performance

Kissei Pharmaceutical has revised its consolidated financial results forecast for the fiscal year ending March 31, 2026. The company now expects net sales of 95,500 million yen, an increase of 4,000 million yen from the previously announced forecast of 91,500 million yen. This improvement is attributed to an expected 2,500 million yen increase in the pharmaceutical business and a 1,500 million yen increase in other businesses.

The revised forecast anticipates an operating loss of 2,600 million yen, an improvement of 1,400 million yen from the initial forecast of a 4,000 million yen loss. Ordinary income is also projected to improve by 1,500 million yen, resulting in a revised loss of 1,100 million yen. Despite an expected rise in the cost of sales ratio in the latter half of the fiscal year, increased net sales are driving these profit improvements.

Profit attributable to owners of parent is now forecast to be 12,700 million yen, an increase of 400 million yen from the initial projection of 12,300 million yen. Basic earnings per share are consequently revised to 305.56 yen, up from 297.07 yen.